{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-21-000054","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2021-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.544579+00:00","generated_at":"2026-06-29T08:35:36.802158+00:00","sec_items":["1.01","2.01","5.02"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Amphastar to acquire remaining ~15% of Nanjing subsidiary for $22.5M cash","bullets":["Signed SPA for ~15% stake in Amphastar Nanjing Pharmaceuticals (ANP) from QQ for ~$22.5M.","Deal subject to regulatory approval; after closing, Amphastar will own 100% of ANP.","QQ is controlled by COO/Chairman Mary Luo, CEO Jack Zhang, and family members.","Proceeds: APCL $18.96M, Bill Zhang $3.37M, Chongqing Zhang $0.21M.","Transaction price based on independent valuation and deemed fair by disinterested directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-21-000054","json":"https://secwatch.observer/filing/0001297184-21-000054.json","markdown":"https://secwatch.observer/filing/0001297184-21-000054.md","text":"https://secwatch.observer/filing/0001297184-21-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718421000054/0001297184-21-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718421000054/amph-20210819x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T08:35:36.802158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}